Zevra Therapeutics, Inc. (ZVRA) has disclosed a new risk, in the Corporate Activity and Growth category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zevra Therapeutics, Inc. may need to secure collaborations with larger pharmaceutical or biotechnology companies to advance and commercialize certain product candidates, yet it faces intense competition for suitable partners and complex, time‑consuming negotiations. Failure to obtain partnerships on acceptable terms could force Zevra to delay or scale back development and commercialization efforts, or to raise additional capital on potentially unfavorable terms, constraining its ability to generate future product revenue.
Overall, Wall Street has a Strong Buy consensus rating on ZVRA stock based on 6 Buys.
To learn more about Zevra Therapeutics, Inc.’s risk factors, click here.